Chinese pharma is about to hit the global market, says a leader of the charge

19 September 2016

British-born Christian Hogg can say with some confidence that the milestone of a Chinese company taking a drug candidate from discovery all the way to global registration will be achieved within the next two to three years.

As the chief executive of Hutchison China MediTech Limited, a biopharma which is majority owned by the conglomerate CK Hutchison Holdings (SEHK: 0001) and has a potentially ground-breaking cancer drug poised to enter Phase III testing in the USA with savolitinib, he also has a very real hope that it will be his company which leads the way, Mr Hogg told The Pharma Letter in an exclusive interview.

Having joined the company, which is known as Chi-Med, at its outset in 2000, Mr Hogg has seen the ingredients coming together to put China on the brink of becoming a major player in global pharma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK